<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT05046613</url>
  </required_header>
  <id_info>
    <org_study_id>BHV3000-402</org_study_id>
    <nct_id>NCT05046613</nct_id>
  </id_info>
  <brief_title>Observational Study to Assess Maternal, Fetal and Infant Outcomes Following Exposure to Rimegepant</brief_title>
  <acronym>MONITOR</acronym>
  <official_title>A Prospective, Registry Based, Observational Study to Assess Maternal, Fetal and Infant Outcomes Following Exposure to Rimegepant: The Migraine Observational Nurtec Pregnancy Registry (MONITOR)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Biohaven Pharmaceuticals, Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Biohaven Pharmaceutical Holding Company Ltd.</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Biohaven Pharmaceuticals, Inc.</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of the study is to evaluate fetal, maternal, and infant outcomes through 12&#xD;
      months of age.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">November 4, 2021</start_date>
  <completion_date type="Anticipated">April 30, 2034</completion_date>
  <primary_completion_date type="Anticipated">April 30, 2034</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Major congenital malformation (birth defect)</measure>
    <time_frame>Annually beginning April 2022</time_frame>
    <description>Healthcare provider report through the registry</description>
  </primary_outcome>
  <number_of_groups>2</number_of_groups>
  <enrollment type="Anticipated">780</enrollment>
  <condition>Migraine</condition>
  <arm_group>
    <arm_group_label>Pregnant women with migraine exposed to Rimegepant</arm_group_label>
  </arm_group>
  <arm_group>
    <arm_group_label>Pregnant women with migraine not exposed to Rimegepant</arm_group_label>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Rimegepant</intervention_name>
    <description>75mg</description>
    <arm_group_label>Pregnant women with migraine exposed to Rimegepant</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Not taking Rimegepant</intervention_name>
    <description>No rimegepant</description>
    <arm_group_label>Pregnant women with migraine not exposed to Rimegepant</arm_group_label>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        The study population will include pregnant women of any age within the US with migraine who&#xD;
        were treated with rimegepant as part of routine care at any time during pregnancy or just&#xD;
        prior to pregnancy (up to 3 days prior to conception), as well as pregnant women with&#xD;
        migraine not exposed to rimegepant before or during pregnancy.&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Pregnant women with migraine exposed to rimegepant: a diagnosis of migraine and at&#xD;
             least 1 dose of rimegepant during pregnancy or just prior to pregnancy (up to 3 days&#xD;
             prior to conception)&#xD;
&#xD;
          -  Pregnant women with migraine unexposed to rimegepant: a diagnosis of migraine and no&#xD;
             exposure to Rimegepant before or during pregnancy&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
        â€¢ Women exposed to other calcitonin gene-related peptide (CGRP)antagonists (e.g.,&#xD;
        ubrogepant), CGRP monoclonal antibodies, or ditans (e.g., lasmiditan) at any time during&#xD;
        pregnancy or just prior to pregnancy&#xD;
      </textblock>
    </criteria>
    <gender>Female</gender>
    <gender_based>Yes</gender_based>
    <minimum_age>N/A</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Elyse Stock, MD</last_name>
    <phone>203-404-0410</phone>
    <email>Clinicaltrials@biohavenpharma.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>PPD</name>
      <address>
        <city>Morrisville</city>
        <state>North Carolina</state>
        <zip>27560</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Kristin Veley, PharmD, MPH</last_name>
      <phone>877-366-0324</phone>
      <email>nurtecpregnancyregistry@ppd.com</email>
    </contact>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>November 2021</verification_date>
  <study_first_submitted>September 8, 2021</study_first_submitted>
  <study_first_submitted_qc>September 8, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">September 16, 2021</study_first_posted>
  <last_update_submitted>November 12, 2021</last_update_submitted>
  <last_update_submitted_qc>November 12, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">November 15, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Migraine, Migraine Headache, Migraine Disorder, Migraine Prevention, Prevention of Migraine, Pregnant, Pregnancy, Infant</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Migraine Disorders</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

